| Literature DB >> 32556443 |
Brittany L Bunch1, Krithika N Kodumudi1, Ellen Scott1, Jennifer Morse1, Amy Mackay Weber1, Anders E Berglund2,3, Shari Pilon-Thomas4,5,6,7, Joseph Markowitz8,9,10.
Abstract
Emm55 is a bacterial gene derived from Streptococcus pyogenes (S. pyogenes) that was cloned into a plasmid DNA vaccine (pAc/emm55). In this study, we investigated the anti-tumor efficacy of pAc/emm55 in a B16 murine melanoma model. Intralesional (IL) injections of pAc/emm55 significantly delayed tumor growth compared to the pAc/Empty group. There was a significant increase in the CD8+ T cells infiltrating into the tumors after pAc/emm55 treatment compared to the control group. In addition, we observed that IL injection of pAc/emm55 increased antigen-specific T cell infiltration into tumors. Depletion of CD4+ or CD8+ T cells abrogated the anti-tumor effect of pAc/emm55. Combination treatment of IL injection of pAc/emm55 with anti-PD-1 antibody significantly delayed tumor growth compared to either monotherapy. pAc/emm55 treatment combined with PD-1 blockade enhanced anti-tumor immune response and improved systemic anti-tumor immunity. Together, these strategies may lead to improvements in the treatment of patients with melanoma.Entities:
Keywords: Bacterial protein; Intralesional injection; Melanoma; Streptococcus pyogenes; emm55
Year: 2020 PMID: 32556443 PMCID: PMC7680263 DOI: 10.1007/s00262-020-02634-4
Source DB: PubMed Journal: Cancer Immunol Immunother ISSN: 0340-7004 Impact factor: 6.968